8-K filed Jul 29, 2026 at 07:11 ET
Axogen reported Q2 2026 revenue of $69.7M (+23.1% YoY), slightly above the $67.1M consensus, and adjusted EPS of $0.12, in line with estimates. The company raised its full-year 2026 revenue guidance to at least $279M (24% growth), up from the prior $270M (20% growth) target, driven by accelerating Breast segment growth (>50% YoY) and expanding commercial insurance coverage. The stock is likely to react positively to the guidance raise and strong top-line momentum, though GAAP net loss widened to -$0.03/share vs +$0.01 a year ago, and adjusted EBITDA margin compressed to 12.1% from 16.3% due to increased investment in sales force and R&D.